Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Covidien Plans April U.S. Launch Of Solitaire For Ischemic Strokes

This article was originally published in The Pink Sheet Daily

Executive Summary

Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.

You may also be interested in...

Research In Brief

New findings on deep brain stimulation, ischemic stroke devices, orthopedics and more.

Covidien Gains Barrett’s Esophagus Ablation Device Via Barrx Acquisition

Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.

Covidien Aims To Double Sales In Emerging Markets By 2017

Covidien plans to double its sales in emerging markets, primarily China and India, to $2 billion over the next five to six years, CEO Jose E. Almeida said during the firm’s Sept. 8 investor meeting in New York.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts